News | EuroPCR | May 05, 2020

EuroPCR Cancels Annual Meeting Due to COVID-19

EuroPCR Cancels Annual Meeting Due to COVID-19. #SARScov2 #COVID19

May 5, 2020 — The large European interventional cardiology conference EuroPCR has been cancelled due to the contenting containment efforts for COVID-19 (SARS-CoV-2).

"The sanitary and legal environment, and in particular the decisions of the French government barring public gatherings for events exceeding 5,000 participants, have resulted in us cancelling the EuroPCR 2020 Course in Paris as a consequence of the COVID-19 outbreak," stated a letter sent out by EuroPCR today from the EuroPCR Course Directors Andreas Baumbach, Alberto Cremonesi, Jean Fajadet and William Wijns.

They said over the last two to three months, the Paris Course on Revascularization (PCR) mission of sharing knowledge, experience and practice has remained more actively relevant than ever with multiple educational resources freely available on PCRonline.

The organizers of the meeting said they will be working with the program committee to provide a full update on late-breaking trials and other essential educational content. Details of the dates and platform to be used will be announced in the coming weeks.

"We reiterate our heartfelt solidarity to all those affected by the coronavirus across the globe and extend our warmest wishes for good health to you and your patients, colleagues and loved ones," the course directors said in the statement. 

For additional information on the status of EuroPCR. 

 

Related Cardiology Conference Cancellations Due to COVID-19:

Cardiology Meetings Continue to be Cancelled or Go Virtual Due to COVID-19

SCCT Plans to Make 2020 Annual Meeting Virtual Due to COVID-19

ACC Cancels 2020 Conference Amid Coronavirus Concerns

Heart Rhythm Society Cancels 2020 Meeting Due to COVID-19

European Heart Rhythm Association Cancelled Due to Coronavirus

 

Related Content

cyanosis, cyantosis COVID-positive infant.

Chest X-ray of a  2-month-old infant diagnosed with COVID-19 showing an enlarged heart, bibasilar opacities caused by collapse of the lower sections of lungs, and right upper lobe atelectasis (lung collapse). Find more information anf figures on this patient case.

 

News | Coronavirus (COVID-19) | December 02, 2020
December 2, 2020 — A 2-month-old infant diagnosed with...
Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. #AHA #AHA20 #AHA2020 #COVID19 #Coronavirus #SARSCoV2

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. 

News | Coronavirus (COVID-19) | November 18, 2020 | Dave Fornell, Editor
November 18, 2020 — A late-breaking study at the 2020 American Heart A...
Black patient being tested for COVID-19 using a nasal swab PCR test. black adults with COVID-19 were far more likely to be hospitalized than their white counterparts according to data from the AHA COVID-19 Cardiovascular Disease Registry. #AHA #AHA20 #AHA2020 #COVID19 #SARSCoV2

Black patient being tested for COVID-19 using a nasal swab PCR test. Black adults with COVID-19 were far more likely to be hospitalized than their white counterparts according to new data from the AHA COVID-19 Cardiovascular Disease Registry. 

Feature | Coronavirus (COVID-19) | November 18, 2020
November 18, 2020 -- A new American Heart Association (AHA) collab
Gallery | Coronavirus (COVID-19) | November 11, 2020 | Dave Fornell, Editor
This photo gallery is designed to show the impact of the...
The impact of COVID-19 on the heart and cardiovascular system is being evaluated in a new clinic for post-COVID patients to monitor and manage their cardiac recovery.
News | Coronavirus (COVID-19) | November 10, 2020
November 10, 2020 — The Smidt Heart Institute at Cedars-Sinai Hospital in Los Angeles has established a specialized c
NIH trial, the Outcomes Related to COVID-19 treated with Hydroxychloroquine among Inpatients with symptomatic Disease (ORCHID), showed no difference in deaths between placebo and hydroxychloroquine. Getty Images
News | Coronavirus (COVID-19) | November 09, 2020 | Dave Fornell, Editor
November 9, 2020 — A National Institutes of Health (NIH) clinical trial evaluating the safety and effectiveness of...